Literature DB >> 34297288

The Increase of Antileukemic Efficiency of Doxorubicin and Other Cytostatics Combined with Platinum(IV)-Nitroxyl Complex ВС118.

S A Goncharova1, T A Raevskaya2, E N Klimanova2, V D Sen'2.   

Abstract

Combined treatment of murine leukemia P388 with doxorubicin and platinum(IV)-nitroxyl complex ВС118 administered in low doses improved efficiency of treatment (cure of 83% of animals) without increasing toxicity.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  antitumor cytostatics; combined therapy; monotherapy; platinum(IV)-nitroxyl complex ВС118; toxicity

Mesh：

Substances：

Year:  2021        PMID： 34297288     DOI： 10.1007/s10517-021-05224-1

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN： 0007-4888            Impact factor:   0.804


  6 in total

1.  [Antileukemic activity and development of resistance to cisplatin (CPT) and platinum (IV)-nitroxyl complex VS118].

Authors:  S A Goncharova; T A Raevskaia; T N Iakushchenko; S V Blokhina; N P Konovalova; V D Sen'
Journal:  Vopr Onkol       Date:  2011

2.  Activity profile of the cisplatin analogue PN149 in different tumor cell lines.

Authors:  Sarah Schoch; Vasily Sen; Sabine Gajewski; Valery Golubev; Bettina Strauch; Andrea Hartwig; Beate Köberle
Journal:  Biochem Pharmacol       Date:  2018-08-20       Impact factor: 5.858

3.  Protective effect of the nitroxide tempol against the cardiotoxicity of adriamycin.

Authors:  E Monti; D Cova; E Guido; R Morelli; C Oliva
Journal:  Free Radic Biol Med       Date:  1996       Impact factor: 7.376

Review 4.  Toxicity of Doxorubicin (Dox) to different experimental organ systems.

Authors:  Arivalagan Pugazhendhi; Thomas Nesakumar Jebakumar Immanuel Edison; Bharath Kumar Velmurugan; Joe Antony Jacob; Indira Karuppusamy
Journal:  Life Sci       Date:  2018-03-10       Impact factor: 5.037

5.  Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide.

Authors:  Hideki Mizutani; Saeko Tada-Oikawa; Yusuke Hiraku; Michio Kojima; Shosuke Kawanishi
Journal:  Life Sci       Date:  2005-01-20       Impact factor: 5.037

Review 6.  Doxil®--the first FDA-approved nano-drug: lessons learned.

Authors:  Yechezkel Barenholz
Journal:  J Control Release       Date:  2012-03-29       Impact factor: 9.776
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.